Navigation Links
Varian Medical Systems Publishes First Sustainability Report Outlining Environmental, Charitable, Safety and Health Access Achievements

PALO ALTO, Calif., Oct. 19 2011 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR), a world leader in radiotherapy and X-Ray imaging technology, is announcing the publication of its first comprehensive Corporate Social Responsibility (CSR) report, detailing the company's policies and achievements in extending care, protecting resources and helping to save lives. The 'Varian Sustainability' Report has been produced as part of the wider investment to continually improve sustainability performance and transparency.

"We have a responsibility to achieve our business goals in a socially and environmentally responsible manner," says Tim Guertin, chief executive officer of Varian Medical Systems. "While our company continues to develop better therapeutic capabilities for fighting cancer and other diseases as well as better components for X-Ray imaging, we strive to do so in ways which extend access to advanced care, improve clinical outcomes, optimize safety and make a positive impact on the communities where we operate."

In 2010, Varian commenced a company-wide undertaking to examine sustainability performance and identify challenges and opportunities to be addressed over time. This effort involved the close participation of senior leaders from all divisions, key geographies, and core functions.

The report, based on internationally-recognized GRI (global reporting initiative) parameters, reiterates the company's stated mission to help save an additional 100,000 lives each year, while outlining the governance structure that determines Varian's sustainability activities and setting goals for future achievements. The report's content is divided into four key areas: environmental, health access and outcomes, safety and responsibility, and colleagues and communities.

The report is available for customers, investors, and the general public at Varian plans to update its sustainability report in mid-2012.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,700 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit or follow us on Twitter.

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
(Date:11/30/2015)... VIEW, Calif. , Nov. 30, 2015 ... been the norm in U.S. medical imaging ... The increasingly popular accountable care payer-provider contracts ... models and, in their wake, alter provider-vendor ... quality-based payments will push forward new purchasing ...
(Date:11/30/2015)... and SAN DIEGO , ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today announced that ... for filing the New Drug Application (NDA) for an ... release formulation will offer patients a chronic weight management ... ® ) is currently approved as an adjunct to ...
(Date:11/30/2015)... and ST. LOUIS , Nov. 30, ... ESRX ) today announced an early renewal of ... began in 1999, will now extend through at least ... After evaluating pharmacy benefit manager capabilities during a ... Scripts continues to offer the best health plan integration ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel insurance ... Television’s Travel With Kids to promote family vacations around the world. The television ... international destinations and educate families about the people and places of the world, all ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... At Grand ... comfortable and convenient setting. , When you have dental problems, you need to turn ... and can effectively diagnose and treat your needs, a friendly dentist who counsels you ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed ... of Glen Ridge, NJ. He has both advanced training and considerable experience ... is also an expert in cosmetic dentistry. He is an active Spear ...
(Date:11/30/2015)... ... November 30, 2015 , ... ”Dying Words: The AIDS Reporting of Jeff Schmalz ... 2015, to coincide with World AIDS Day. The multi-media project will be in audio ... epidemic as he was dying of the disease. , A collaborative effort led by ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
Breaking Medicine News(10 mins):